...College London ; Oxford Biomedica plc (LSE:OXB); University of Oxford ; University of Edinburgh ; Imperial Innovations...

...to develop a gene therapy to treat cystic fibrosis. Partners include Oxford BioMedica plc (LSE:OXB), Imperial Innovations...
...Financial terms were undisclosed. Boehringer Ingelheim GmbH, Ingelheim, Germany Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Imperial Innovations...
...Oxford, Oxford, U.K. University of Edinburgh, Edinburgh, U.K. Business: Pulmonary Michael von Emster Boehringer Ingelheim GmbH Imperial College London Imperial Innovations...

...U.K.) hired Tony Hickson as CBO, effective in August. He is managing director at the Imperial Innovations...

...a timeline. The company raised $28.6 million in a 2013 series A round led by Imperial Innovations...

...But there’s an interesting model seen with BTG plc , IP Group plc , and Imperial Innovations...

...2016 with £40 million ($57 million) by UCL, Cambridge University and Imperial College London ’s Imperial Innovations...

...an undisclosed sum. Pulmocide also has three investors in common with RespiVert: SV Life Sciences, Imperial Innovations...

...£4 million ($5 million) in a venture round led by existing investors Epidarex Capital and Imperial Innovations...

...partners: None Number of employees: 14 Funds raised: £7 million ($8.6 million) Investors: Brandon Capital, Imperial Innovations...

...2016-09-21 Type: Venture financing Raised: $33.2 million Investors: SV Life Sciences ; Merck Ventures B.V.; Imperial Innovations...